APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Drug Repurposing Platform

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Drug Repurposing Platform Market Outlook and Growth Opportunities 2026

12 August 2026196 pages

Choose your research edition.

Industry ResearchAI Drug Repurposing Platform Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Drug Repurposing Platform Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal AI Drug Repurposing Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Drug Repurposing Platform Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Drug Repurposing Platform Market Analysis and Forecast 2026-2032178 pages · $4,950 USD

Market perspective

The global AI Drug Repurposing Platform market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Drug Repurposing Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Drug Repurposing Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Drug Repurposing Platform is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Drug Repurposing Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Drug Repurposing Platform market include Recursion, Lantern Pharma, SOM Biotech, Standigm, Pharos iBio, Aitia, Causaly, BenevolentAI and Healx, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Drug Repurposing Platform market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Drug Repurposing Platform and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Drug Repurposing Platform revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Drug Repurposing Platform market.

AI Drug Repurposing Platform Segment by Company

Recursion

Lantern Pharma

SOM Biotech

Standigm

Pharos iBio

Aitia

Causaly

BenevolentAI

Healx

Insilico Medicine

AI Drug Repurposing Platform Segment by Type

Target and Mechanism Mining

Drug–Disease Matching

Indication Expansion

Combination Therapy Prediction

Evidence Ranking and Validation

Safety and Translational Assessment

AI Drug Repurposing Platform Segment by Application

Rare Disease Repurposing

Oncology Indication Expansion

Infectious Disease Response

CNS and Neurology Research

Immunology and Inflammation Research

Asset Rescue and Pipeline Optimization

AI Drug Repurposing Platform Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Drug Repurposing Platform status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Drug Repurposing Platform key companies, revenue, market share, and recent developments.

3. To split the AI Drug Repurposing Platform breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Drug Repurposing Platform market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Drug Repurposing Platform significant trends, drivers, influence factors in global and regions.

6. To analyze AI Drug Repurposing Platform competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Drug Repurposing Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Drug Repurposing Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Drug Repurposing Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Drug Repurposing Platform industry.

Chapter 3: Detailed analysis of AI Drug Repurposing Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Drug Repurposing Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Drug Repurposing Platform in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Drug Repurposing Platform Industry Trends Table 2. AI Drug Repurposing Platform Industry Drivers Table 3. AI Drug Repurposing Platform Industry Opportunities and Challenges Table 4. AI Drug Repurposing Platform Industry Restraints Table 5. Global AI Drug Repurposing Platform Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Drug Repurposing Platform Revenue Share by Company (2021-2026) Table 7. Global AI Drug Repurposing Platform Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Drug Repurposing Platform Key Company Manufacturing Base & Headquarters Table 9. Global AI Drug Repurposing Platform Company, Product Type & Application Table 10. Global AI Drug Repurposing Platform Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Drug Repurposing Platform by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Target and Mechanism Mining Table 15. Significant Companies of Drug–Disease Matching Table 16. Significant Companies of Indication Expansion Table 17. Significant Companies of Combination Therapy Prediction Table 18. Significant Companies of Evidence Ranking and Validation Table 19. Significant Companies of Safety and Translational Assessment Table 20. Global AI Drug Repurposing Platform Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global AI Drug Repurposing Platform Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global AI Drug Repurposing Platform Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global AI Drug Repurposing Platform Sales Value Share by Type (2021-2026) Table 24. Global AI Drug Repurposing Platform Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Rare Disease Repurposing Table 26. Significant Companies of Oncology Indication Expansion Table 27. Significant Companies of Infectious Disease Response Table 28. Significant Companies of CNS and Neurology Research Table 29. Significant Companies of Immunology and Inflammation Research Table 30. Significant Companies of Asset Rescue and Pipeline Optimization Table 31. Global AI Drug Repurposing Platform Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global AI Drug Repurposing Platform Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global AI Drug Repurposing Platform Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global AI Drug Repurposing Platform Sales Value Share by Application (2021-2026) Table 35. Global AI Drug Repurposing Platform Sales Value Share by Application (2027-2032) Table 36. Global AI Drug Repurposing Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global AI Drug Repurposing Platform Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global AI Drug Repurposing Platform Sales Value Share by Region (2021-2026) Table 39. Global AI Drug Repurposing Platform Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global AI Drug Repurposing Platform Sales Value Share by Region (2027-2032) Table 41. Global AI Drug Repurposing Platform Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global AI Drug Repurposing Platform Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global AI Drug Repurposing Platform Sales Value Market Share by Country (2021-2026) Table 44. Global AI Drug Repurposing Platform Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global AI Drug Repurposing Platform Sales Value Market Share by Country (2027-2032) Table 46. Recursion Company Information Table 47. Recursion Business Overview Table 48. Recursion AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Recursion AI Drug Repurposing Platform Product Portfolio Table 50. Recursion Recent Development Table 51. Lantern Pharma Company Information Table 52. Lantern Pharma Business Overview Table 53. Lantern Pharma AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Lantern Pharma AI Drug Repurposing Platform Product Portfolio Table 55. Lantern Pharma Recent Development Table 56. SOM Biotech Company Information Table 57. SOM Biotech Business Overview Table 58. SOM Biotech AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. SOM Biotech AI Drug Repurposing Platform Product Portfolio Table 60. SOM Biotech Recent Development Table 61. Standigm Company Information Table 62. Standigm Business Overview Table 63. Standigm AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Standigm AI Drug Repurposing Platform Product Portfolio Table 65. Standigm Recent Development Table 66. Pharos iBio Company Information Table 67. Pharos iBio Business Overview Table 68. Pharos iBio AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pharos iBio AI Drug Repurposing Platform Product Portfolio Table 70. Pharos iBio Recent Development Table 71. Aitia Company Information Table 72. Aitia Business Overview Table 73. Aitia AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Aitia AI Drug Repurposing Platform Product Portfolio Table 75. Aitia Recent Development Table 76. Causaly Company Information Table 77. Causaly Business Overview Table 78. Causaly AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Causaly AI Drug Repurposing Platform Product Portfolio Table 80. Causaly Recent Development Table 81. BenevolentAI Company Information Table 82. BenevolentAI Business Overview Table 83. BenevolentAI AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. BenevolentAI AI Drug Repurposing Platform Product Portfolio Table 85. BenevolentAI Recent Development Table 86. Healx Company Information Table 87. Healx Business Overview Table 88. Healx AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Healx AI Drug Repurposing Platform Product Portfolio Table 90. Healx Recent Development Table 91. Insilico Medicine Company Information Table 92. Insilico Medicine Business Overview Table 93. Insilico Medicine AI Drug Repurposing Platform Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Insilico Medicine AI Drug Repurposing Platform Product Portfolio Table 95. Insilico Medicine Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. AI Drug Repurposing Platform Product Image Figure 2. Global AI Drug Repurposing Platform Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Drug Repurposing Platform Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Drug Repurposing Platform Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Target and Mechanism Mining Image Figure 8. Drug–Disease Matching Image Figure 9. Indication Expansion Image Figure 10. Combination Therapy Prediction Image Figure 11. Evidence Ranking and Validation Image Figure 12. Safety and Translational Assessment Image Figure 13. Global AI Drug Repurposing Platform Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global AI Drug Repurposing Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global AI Drug Repurposing Platform Sales Value Share by Type (2021-2032) Figure 16. Rare Disease Repurposing Image Figure 17. Oncology Indication Expansion Image Figure 18. Infectious Disease Response Image Figure 19. CNS and Neurology Research Image Figure 20. Immunology and Inflammation Research Image Figure 21. Asset Rescue and Pipeline Optimization Image Figure 22. Global AI Drug Repurposing Platform Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global AI Drug Repurposing Platform Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global AI Drug Repurposing Platform Sales Value Share by Application (2021-2032) Figure 25. Global AI Drug Repurposing Platform Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global AI Drug Repurposing Platform Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America AI Drug Repurposing Platform Sales Value (2021-2032) & (US$ Million) Figure 28. North America AI Drug Repurposing Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe AI Drug Repurposing Platform Sales Value (2021-2032) & (US$ Million) Figure 30. Europe AI Drug Repurposing Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific AI Drug Repurposing Platform Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific AI Drug Repurposing Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America AI Drug Repurposing Platform Sales Value (2021-2032) & (US$ Million) Figure 34. South America AI Drug Repurposing Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa AI Drug Repurposing Platform Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa AI Drug Repurposing Platform Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Target and Mechanism Mining
  • Drug–Disease Matching
  • Indication Expansion
  • Combination Therapy Prediction
  • Evidence Ranking and Validation
  • Safety and Translational Assessment
Applications
  • Rare Disease Repurposing
  • Oncology Indication Expansion
  • Infectious Disease Response
  • CNS and Neurology Research
  • Immunology and Inflammation Research
  • Asset Rescue and Pipeline Optimization
Companies covered
  • Recursion
  • Lantern Pharma
  • SOM Biotech
  • Standigm
  • Pharos iBio
  • Aitia
  • Causaly
  • BenevolentAI
  • Healx
  • Insilico Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Drug Repurposing Platform Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Drug Repurposing Platform Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Drug Repurposing Platform Market Dynamics
  1. 2.1 AI Drug Repurposing Platform Industry Trends
  2. 2.2 AI Drug Repurposing Platform Industry Drivers
  3. 2.3 AI Drug Repurposing Platform Industry Opportunities and Challenges
  4. 2.4 AI Drug Repurposing Platform Industry Restraints
3 AI Drug Repurposing Platform Market by Company
  1. 3.1 Global AI Drug Repurposing Platform Company Revenue Ranking in 2025
  2. 3.2 Global AI Drug Repurposing Platform Revenue by Company (2021-2026)
  3. 3.3 Global AI Drug Repurposing Platform Company Ranking (2024-2026)
  4. 3.4 Global AI Drug Repurposing Platform Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Drug Repurposing Platform Company Product Type and Application
  6. 3.6 Global AI Drug Repurposing Platform Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Drug Repurposing Platform Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Drug Repurposing Platform Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Drug Repurposing Platform Market by Type
  1. 4.1 AI Drug Repurposing Platform Type Introduction
  2. 4.1.1 Target and Mechanism Mining
  3. 4.1.2 Drug–Disease Matching
  4. 4.1.3 Indication Expansion
  5. 4.1.4 Combination Therapy Prediction
  6. 4.1.5 Evidence Ranking and Validation
  7. 4.1.6 Safety and Translational Assessment
  8. 4.2 Global AI Drug Repurposing Platform Sales Value by Type
  9. 4.2.1 Global AI Drug Repurposing Platform Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global AI Drug Repurposing Platform Sales Value by Type (2021-2032)
  11. 4.2.3 Global AI Drug Repurposing Platform Sales Value Share by Type (2021-2032)
5 AI Drug Repurposing Platform Market by Application
  1. 5.1 AI Drug Repurposing Platform Application Introduction
  2. 5.1.1 Rare Disease Repurposing
  3. 5.1.2 Oncology Indication Expansion
  4. 5.1.3 Infectious Disease Response
  5. 5.1.4 CNS and Neurology Research
  6. 5.1.5 Immunology and Inflammation Research
  7. 5.1.6 Asset Rescue and Pipeline Optimization
  8. 5.2 Global AI Drug Repurposing Platform Sales Value by Application
  9. 5.2.1 Global AI Drug Repurposing Platform Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global AI Drug Repurposing Platform Sales Value by Application (2021-2032)
  11. 5.2.3 Global AI Drug Repurposing Platform Sales Value Share by Application (2021-2032)
6 AI Drug Repurposing Platform Regional Value Analysis
  1. 6.1 Global AI Drug Repurposing Platform Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Drug Repurposing Platform Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Drug Repurposing Platform Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Drug Repurposing Platform Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Drug Repurposing Platform Sales Value (2021-2032)
  7. 6.3.2 North America AI Drug Repurposing Platform Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Drug Repurposing Platform Sales Value (2021-2032)
  10. 6.4.2 Europe AI Drug Repurposing Platform Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Drug Repurposing Platform Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Drug Repurposing Platform Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Drug Repurposing Platform Sales Value (2021-2032)
  16. 6.6.2 South America AI Drug Repurposing Platform Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Drug Repurposing Platform Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Drug Repurposing Platform Sales Value Share by Country, 2025 VS 2032
7 AI Drug Repurposing Platform Country-level Value Analysis
  1. 7.1 Global AI Drug Repurposing Platform Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Drug Repurposing Platform Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Drug Repurposing Platform Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Drug Repurposing Platform Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Drug Repurposing Platform Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Drug Repurposing Platform Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Drug Repurposing Platform Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Recursion
  2. 8.1.1 Recursion Company Information
  3. 8.1.2 Recursion Business Overview
  4. 8.1.3 Recursion AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Recursion AI Drug Repurposing Platform Product Portfolio
  6. 8.1.5 Recursion Recent Developments
  7. 8.2 Lantern Pharma
  8. 8.2.1 Lantern Pharma Company Information
  9. 8.2.2 Lantern Pharma Business Overview
  10. 8.2.3 Lantern Pharma AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lantern Pharma AI Drug Repurposing Platform Product Portfolio
  12. 8.2.5 Lantern Pharma Recent Developments
  13. 8.3 SOM Biotech
  14. 8.3.1 SOM Biotech Company Information
  15. 8.3.2 SOM Biotech Business Overview
  16. 8.3.3 SOM Biotech AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SOM Biotech AI Drug Repurposing Platform Product Portfolio
  18. 8.3.5 SOM Biotech Recent Developments
  19. 8.4 Standigm
  20. 8.4.1 Standigm Company Information
  21. 8.4.2 Standigm Business Overview
  22. 8.4.3 Standigm AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Standigm AI Drug Repurposing Platform Product Portfolio
  24. 8.4.5 Standigm Recent Developments
  25. 8.5 Pharos iBio
  26. 8.5.1 Pharos iBio Company Information
  27. 8.5.2 Pharos iBio Business Overview
  28. 8.5.3 Pharos iBio AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharos iBio AI Drug Repurposing Platform Product Portfolio
  30. 8.5.5 Pharos iBio Recent Developments
  31. 8.6 Aitia
  32. 8.6.1 Aitia Company Information
  33. 8.6.2 Aitia Business Overview
  34. 8.6.3 Aitia AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Aitia AI Drug Repurposing Platform Product Portfolio
  36. 8.6.5 Aitia Recent Developments
  37. 8.7 Causaly
  38. 8.7.1 Causaly Company Information
  39. 8.7.2 Causaly Business Overview
  40. 8.7.3 Causaly AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Causaly AI Drug Repurposing Platform Product Portfolio
  42. 8.7.5 Causaly Recent Developments
  43. 8.8 BenevolentAI
  44. 8.8.1 BenevolentAI Company Information
  45. 8.8.2 BenevolentAI Business Overview
  46. 8.8.3 BenevolentAI AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BenevolentAI AI Drug Repurposing Platform Product Portfolio
  48. 8.8.5 BenevolentAI Recent Developments
  49. 8.9 Healx
  50. 8.9.1 Healx Company Information
  51. 8.9.2 Healx Business Overview
  52. 8.9.3 Healx AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Healx AI Drug Repurposing Platform Product Portfolio
  54. 8.9.5 Healx Recent Developments
  55. 8.10 Insilico Medicine
  56. 8.10.1 Insilico Medicine Company Information
  57. 8.10.2 Insilico Medicine Business Overview
  58. 8.10.3 Insilico Medicine AI Drug Repurposing Platform Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Insilico Medicine AI Drug Repurposing Platform Product Portfolio
  60. 8.10.5 Insilico Medicine Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst